Altimmune's MASH Drug Shows Promise in Extended Trial Despite Mixed Signals

Altimmune (ALT) reports 48-week results for pemvidutide in MASH trial, showing continued weight loss and liver fibrosis improvements, though some measures weakened from earlier data.